Ron Lanton, partner, Lanton Law, explains why evolving federal guidance and new technologies are pushing clinical operations teams to strengthen oversight and safeguard the credibility of clinical ...

Autonomix Medical (Nasdaq:AMIX) announced today that it advanced its proprietary sensing catheter through a final design ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI and digital twins are helping clinical trials become more efficient, patient-centric, and capable of supporting innovative study ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Anxiety symptoms among U.S. adults, even during the COVID-19 pandemic, appear to have remained stable, according to a massive ...

Microchip-based platform enables real-time nerve mapping and targeted treatment from within the vascular system Continued progress toward submitting Investigational Device Exemption ("IDE"), and if ap ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 clinical study titled ‘A Phase 3, ...

Discover DiaMedica Therapeutics' Q2 2025 earnings call highlights: promising preeclampsia trial results, progress in stroke programs & a $60M extended ...

Celgene Corporation (($CELG)) announced an update on their ongoing clinical study. Study Overview: Celgene Corporation is conducting a clinical ...

It is vital that clinical trials for patients with cancer shift to a more representative approach to accurately reflect ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.